MedTrace Logo

Ocular Hypotensive Efficacy of AR-102

NCT00523250 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2014-05-08

No results posted yet for this study

Summary

A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be different from that of its vehicle.

Conditions

Interventions

DRUG

AR-102 0.003% Ophthalmic Solution

DRUG

AR-102 0.005% Ophthalmic Solution

DRUG

AR-102 0.01% Ophthalmic Solution

DRUG

AR-102 0.03% Ophthalmic Solution

DRUG

AR-102 Vehicle Ophthalmic Solution

Sponsors & Collaborators

  • Aerie Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Thomas Van Haarlem, MD · Aerie Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523250 on ClinicalTrials.gov